Activation of NFκB Represents the Central Event in the Neoplastic Progression Associated with Barrett's Esophagus: A Possible Link to the Inflammation and Overexpression of COX-2, PPARγ and Growth Factors
- 1 August 2004
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 49 (7-8) , 1075-1083
Abstract
The molecular mechanisms responsible for the progression of malignant transformation in Barrett's esophagus (BE) are still poorly understood. This study was undertaken (1) to investigate the gene and protein expression of cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor-gamma (PPARγ), interleukin-8 (IL-8), hepatocyte growth factor (HGF), gastrin, and its receptor (CCK-2) in the Barrett's epithelium; (2) to analyze the activity of NFκB in Barrett's esophagus with low-grade dysplasia; and (3) to assess the effects of PPARγ ligand (ciglitazone) and gastrin on cell proliferation in the cell line derived from esophageal adenocarcinoma (OE-33). COX-2, PPARγ, IL-8, HGF, gastrin, and CCK-2 expression levels relative to the control gene encoding GAPDH were analyzed by RT-PCR and Western blot in specimens of BE with low-grade dysplasia (n = 20) and compared with that in the normal squamous esophageal mucosa from the middle portion of the esophagus (n = 20). In vitro experiments included the incubation of cell line OE-33 with ciglitazone (1–15 μ M) and gastrin (100 nM). NFκB activity in biopsies specimens was measured by highly sensitive ELISA. COX-2, PPARγ, IL-8, HGF, gastrin, and CCK-2 expressions were significantly increased in BE compared with normal squamous esophageal mucosa. NFκB activity was significantly upregulated in BE. Ciglitazone inhibited cell proliferation of OE-33 cells as assessed by BrdU and this effect was attenuated partly by gastrin. (1) COX-2, PPARγ, HGF, gastrin, and its receptor are significantly upregulated in BE, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFκB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARγ ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.Keywords
This publication has 44 references indexed in Scilit:
- Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancyAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancerOncogene, 2003
- Therapeutic potential of thiazolidinediones as anticancer agentsExpert Opinion on Investigational Drugs, 2003
- IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesisThe FASEB Journal, 2003
- Gastrin activates nuclear factor κB (NFκB) through a protein kinase C dependent pathway involving NFκB inducing kinase, inhibitor κB (IκB) kinase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptorGut, 2003
- Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl‐2, and gastrin in human gastric cancerAlimentary Pharmacology & Therapeutics, 2001
- The Gastrins: Their Production and Biological ActivitiesAnnual Review of Physiology, 2001
- Hepatocyte growth factor/scatter factor‐induced intracellular signallingInternational Journal of Experimental Pathology, 2000
- Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cellsFEBS Letters, 1999
- Src-family Tyrosine Kinases in Activation of ERK-1 and p85/p110-phosphatidylinositol 3-Kinase by G/CCKBReceptorsJournal of Biological Chemistry, 1999